Addex Therapeutics Ltd. (ADXN)
3.75
-0.30
(-7.41%)
USD |
NASDAQ |
Aug 25, 16:00
3.79
+0.04
(+1.07%)
After-Hours: 18:03
Addex Therapeutics Enterprise Value : 2.990M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.990M |
| August 21, 2026 | 3.875M |
| August 20, 2026 | 3.508M |
| August 19, 2026 | 4.631M |
| August 18, 2026 | 4.631M |
| August 17, 2026 | 4.631M |
| August 14, 2026 | 4.880M |
| August 13, 2026 | 4.880M |
| August 12, 2026 | 4.880M |
| August 11, 2026 | 4.880M |
| August 10, 2026 | 4.880M |
| August 07, 2026 | 4.730M |
| August 06, 2026 | 4.730M |
| August 05, 2026 | 4.621M |
| August 04, 2026 | 4.621M |
| August 03, 2026 | 4.134M |
| July 31, 2026 | 4.134M |
| July 30, 2026 | 4.527M |
| July 29, 2026 | 4.815M |
| July 28, 2026 | 4.815M |
| July 27, 2026 | 4.815M |
| July 24, 2026 | 4.815M |
| July 23, 2026 | 4.815M |
| July 22, 2026 | 4.815M |
| July 21, 2026 | 4.825M |
| Date | Value |
|---|---|
| July 20, 2026 | 4.532M |
| July 17, 2026 | 4.626M |
| July 16, 2026 | 4.870M |
| July 15, 2026 | 5.113M |
| July 14, 2026 | 4.730M |
| July 13, 2026 | 4.641M |
| July 10, 2026 | 5.267M |
| July 09, 2026 | 4.820M |
| July 08, 2026 | 4.820M |
| July 07, 2026 | 4.720M |
| July 06, 2026 | 4.720M |
| July 02, 2026 | 4.720M |
| July 01, 2026 | 4.651M |
| June 30, 2026 | 4.631M |
| June 29, 2026 | 4.929M |
| June 26, 2026 | 4.999M |
| June 25, 2026 | 4.870M |
| June 24, 2026 | 4.929M |
| June 23, 2026 | 5.377M |
| June 22, 2026 | 5.446M |
| June 18, 2026 | 5.128M |
| June 17, 2026 | 5.138M |
| June 16, 2026 | 5.138M |
| June 15, 2026 | 4.929M |
| June 12, 2026 | 5.377M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novartis AG | 330.99B |
| Roche Holding AG | -- |
| Oculis Holding AG | 533.73M |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.184M |
| Revenue (Quarterly) | 0.0098M |
| Total Expenses (Quarterly) | 2.194M |
| EPS Diluted (Quarterly) | -2.211 |
| Gross Profit Margin (Quarterly) | -27.55% |
| Profit Margin (Quarterly) | -22.29K% |
| Earnings Yield | -248.2% |
| Normalized Earnings Yield | -248.20 |